Autoantibodies to the functionally active RING-domain of Ro52/SSA are associated with disease activity in patients with lupus

Lupus

Volumn 22, Issue 5, 2013, Pages 477-485

  Kvarnstrom M ^a   Dzikaite Ottosson, V ^a   Ottosson, L ^a   Gustafsson, J T ^a   Gunnarsson, I ^a   Svenungsson, E ^a   Wahren Herlenius, M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Autoantibodies; E3 ligase; Ro52; systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LA ANTIBODY; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; RO52 ANTIBODY; RO52 B BOX ANTIBODY; RO52 RING ANTIBODY; SM ANTIBODY; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ARTHRITIS; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; EPILEPSY; FEMALE; HEMOLYTIC ANEMIA; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL PARAMETERS; LEUKOCYTE; LEUKOPENIA; LYMPHOCYTE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NEPHRITIS; PERICARDITIS; PHOTOSENSITIVITY; PLEURISY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PSYCHOSIS; RASH; RING FINGER MOTIF; SEDIMENTATION RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

ADULT; AUTOANTIBODIES; AUTOANTIGENS; FEMALE; HUMANS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RIBONUCLEOPROTEINS;

EID: 84875948771     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313479420     Document Type: Article

References (38)

1. Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol. 2005 ; 19: 685-708
2. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1989 ; 32: 1107-1118
3. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 ; 35: 630-640
4. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996 ; 39: 363-369
5. Eriksson C, Kokkonen H, Johansson M, et al. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther. 2011 ; 13: R30 - R30
6. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003 ; 349: 1526-1533
7. Wolin SL, Steitz JA. The Ro small cytoplasmic ribonucleoproteins: Identification of the antigenic protein and its binding site on the Ro RNAs. Proc Natl Acad Sci USA. 1984 ; 81: 1996-2000
8. Espinosa A, Zhou W, Ek M, et al. The Sjogren's syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol. 2006 ; 176: 6277-6285
9. Bonifacino JS, Weissman AM. Ubiquitin and the control of protein fate in the secretory and endocytic pathways. Annu Rev Cell Dev Biol. 1998 ; 14: 19-57
10. Weissman AM. Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol. 2001 ; 2: 169-178
11. Ottosson L, Hennig J, Espinosa A, et al. Structural, functional and immunologic characterization of folded subdomains in the Ro52 protein targeted in Sjogren's syndrome. Mol Immunol. 2006 ; 43: 588-598
12. Espinosa A, Hennig J, Ambrosi A, et al. Anti-Ro52 autoantibodies from patients with Sjogren's syndrome inhibit the Ro52 E3 ligase activity by blocking the E3/E2 interface. J Biol Chem. 2011 ; 286: 36478-36491
13. Kong HJ, Anderson DE, Lee CH, et al. Cutting edge: Autoantigen Ro52 is an interferon inducible E3 ligase that ubiquitinates IRF-8 and enhances cytokine expression in macrophages. J Immunol. 2007 ; 179: 26-30
14. Higgs R, Lazzari E, Wynne C, et al. Self protection from anti-viral responses: Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-Like receptors. PLoS One. 2010 ; 5: e11776 - e11776
15. Espinosa A, Dardalhon V, Brauner S, et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med. 2009 ; 206: 1661-1671
16. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 ; 25: 1271-1277
17. Gustafsson J, Simard JF, Gunnarsson I, et al. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther. 2012 ; 14: R46 - R46
18. Svenungsson E, Gunnarsson I, Fei GZ, et al. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum. 2003 ; 48: 2533-2540
19. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002 ; 61: 554-558
20. Salomonsson S, Dorner T, Theander E, et al. A serologic marker for fetal risk of congenital heart block. Arthritis Rheum. 2002 ; 46: 1233-1241
21. Ottosson L, Salomonsson S, Hennig J, et al. Structurally derived mutations define congenital heart block-related epitopes within the 200-239 amino acid stretch of the Ro52 protein. Scand J Immunol. 2005 ; 61: 109-118
22. Wahren M, Tengner P, Gunnarsson I, et al. Ro/SS-A and La/SS-B antibody level variation in patients with Sjogren's syndrome and systemic lupus erythematosus. J Autoimmun. 1998 ; 11: 29-38
23. Popovic K, Brauner S, Ek M, Wahren-Herlenius M, Nyberg F. Fine specificity of the Ro/SSA autoantibody response in relation to serological and clinical findings in 96 patients with self-reported cutaneous symptoms induced by the sun. Lupus. 2007 ; 16: 10-17
24. Bengtsson AA, Sturfelt G, Truedsson L, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus. 2000 ; 9: 664-671
25. Hay EM, Bacon PA, Gordon C, et al. The BILAG index: A reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993 ; 86: 447-458
26. Ahlin E, Mathsson L, Eloranta ML, et al. Autoantibodies associated with RNA are more enriched than anti-dsDNA antibodies in circulating immune complexes in SLE. Lupus. 2012 ; 21: 586-595
27. Lindop R, Arentz G, Thurgood LA, et al. Pathogenicity and proteomic signatures of autoantibodies to Ro and La. Immunol Cell Biol. 2012 ; 90: 304-309
28. Baer AN, Maynard JW, Shaikh F, Magder LS, Petri M. Secondary Sjogren's syndrome in systemic lupus erythematosus defines a distinct disease subset. J Rheumatol. 2010 ; 37: 1143-1149
29. Manoussakis MN, Georgopoulou C, Zintzaras E, et al. Sjogren's syndrome associated with systemic lupus erythematosus: Clinical and laboratory profiles and comparison with primary Sjogren's syndrome. Arthritis Rheum. 2004 ; 50: 882-891
30. Boulware DW, Hedgpeth MT. Lupus pneumonitis and anti-SSA(Ro) antibodies. J Rheumatol. 1989 ; 16: 479-481
31. Mittoo S, Gelber AC, Hitchon CA, et al. Clinical and serologic factors associated with lupus pleuritis. J Rheumatol. 2010 ; 37: 747-753
32. Yee CS, Hussein H, Skan J, et al. Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. Rheumatology (Oxford). 2003 ; 42: 276-279
33. Gustafsson J, Gunnarsson I, Borjesson O, et al. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus: A prospective cohort study. Arthritis Res Ther. 2009 ; 11: R186 - R186
34. Meilof JF, Veldhoven CH, Swaak AJ, Smeenk RJ. Production of anti-Ro/SS-A and anti-La/SS-B autoantibodies is closely coordinated in systemic lupus erythematosus and independent of anti-dsDNA production. J Autoimmun. 1997 ; 10: 67-75
35. Praprotnik S, Bozic B, Kveder T, Rozman B. Fluctuation of anti-Ro/SS-A antibody levels in patients with systemic lupus erythematosus and Sjogren's syndrome: A prospective study. Clin Exp Rheumatol. 1999 ; 17: 63-68
36. Strandberg L, Salomonsson S, Bremme K, Sonesson S, Wahren-Herlenius M. Ro52, Ro60 and La IgG autoantibody levels and Ro52 IgG subclass profiles longitudinally throughout pregnancy in congenital heart block risk pregnancies. Lupus. 2006 ; 15: 346-353
37. Vitali C, Bencivelli W, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. I. A descriptive analysis of 704 European lupus patients. European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol. 1992 ; 10: 527-539
38. Peschken CA, Katz SJ, Silverman E, et al. The 1000 Canadian faces of lupus: Determinants of disease outcome in a large multiethnic cohort. J Rheumatol. 2009 ; 36: 1200-1208